In this episode of The Rob & Jai Show, Michael O’Rourke, CEO of Re-Vana Therapeutics, joins Dr. Rob Rothman and Dr. Jai Parekh to explore the next-generation of sustained drug delivery in ophthalmology. With millions of intravitreal injections administered annually for retinal diseases like AMD, the need for longer-lasting, more effective treatments has never been greater.

O’Rourke explains how Re-Vana’s proprietary hydrogel-based technologies are setting a new standard for biodegradable, sustained-release drug implants—offering six to twelve months of therapeutic coverage without the need for surgery. The discussion covers:

🔹How Re-Vana’s EyeLief™ and OcuLief™ technologies work to deliver biologics efficiently over extended periods.
🔹Why reducing injection frequency is critical for patient compliance, physician workflow, and overall treatment success.
🔹 The company’s clinical and investment strategy, including a $70M Series B raise to advance its lead asset, a six-month biodegradable fluocinolone acetonide implant.
🔹 The role of strategic partnerships in accelerating innovation, as major pharma companies seek delivery solutions for their retinal therapeutics.
🔹 The global impact of sustained-release biologics, and how Re-Vana is positioning itself as a leader in both the U.S. and European markets.

With a team of seasoned industry experts, strong investor backing, and an unwavering commitment to innovation, Re-Vana Therapeutics is redefining how we approach retinal disease treatment.

Don’t miss this insightful conversation—subscribe to the OIS podcast today and stay ahead of the curve in ophthalmic innovation!